# US 2017/0281774 A1 · Linaclotide compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281774 A1
- Document ID: US20170281774A1
- Status: Published application
- Kind: A1
- Application number: 15/461,923
- Filed: 2017-03-17
- Published: 2017-10-05
- Earliest claimed: 2012-07-12
- Assignees: Forest Laboratories Holdings Limited
- Applicants: Forest Laboratories Holdings Limited
- Inventors: Ritesh Sanghvi; Matthew Miller; Andreas Grill; Yun Mo; Mohammad Mafruhul Bari; Matthew Ronsheim; Joseph Stainkamp
- Web page: https://patentgrep.com/patent/US20170281774A1

## CPC

- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/5015: {Organic compounds, e.g. fats, sugars}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is directed to stable linaclotide compositions and methods of treating gastrointestinal disorders in patients in need thereof by providing the stable linaclotide compositions.

## Claims

### Claim 1

A linaclotide composition comprising linaclotide, a sterically hindered primary amine, a divalent metal cation and a formaldehyde scavenger compound.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition further comprises a peptide having the structure of formula (I) or a pharmaceutically acceptable salt thereof:

### Claim 3 (depends on 2)

The composition of claim 2, wherein the linaclotide composition comprises the peptide of formula (I) in a concentration of up to 5% by weight as compared to the weight of linaclotide.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the linaclotide composition comprises the peptide of formula (I) in a concentration of up to 3% by weight as compared to the weight of linaclotide.

### Claim 5 (depends on 2)

The composition of claim 2, wherein the linaclotide composition comprises the peptide of formula (I) in a concentration of up to 2% by weight as compared to the weight of linaclotide.

### Claim 6 (depends on 2)

The composition of claim 2, wherein the linaclotide composition comprises the peptide of formula (I) in a concentration of up to 1% by weight as compared to the weight of linaclotide.

### Claim 7

A linaclotide composition comprising a formaldehyde scavenger compound and an oral pharmaceutical dosage form comprising about 145 μg or about 29 μg of linaclotide or a pharmaceutically acceptable salt thereof, Ca2+ or a salt thereof, leucine, and a peptide having the structure of formula (I) or a pharmaceutically acceptable salt thereof:

### Claim 8 (depends on 7)

The composition of claim 7, wherein the peptide of formula (I) is present in the oral pharmaceutical dosage form in an amount of about 0.001 to about 2 wt. % relative to the total weight of the dosage form.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the peptide of formula (I) is present in the oral pharmaceutical dosage form in an amount of about 0.001 to about 1 wt. % relative to the total weight of the dosage form.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the peptide of formula (I) is present in the oral pharmaceutical dosage form in an amount of about 0.001 to about 0.75 wt. % relative to the total weight of the dosage form.

### Claim 11 (depends on 7)

The composition of claim 7, wherein the peptide of formula (I) is present in the oral pharmaceutical dosage form in an amount of about 0.001 to about 0.5 wt. % relative to the total weight of the dosage form.

### Claim 12 (depends on 2)

The composition of claim 2, wherein the divalent metal cation is Ca2+ or a salt thereof, the sterically hindered primary amine is leucine, and wherein the linaclotide composition comprises a molar ratio of divalent metal cation:sterically hindered primary amine:linaclotide of about 57-63:28-32:1

### Claim 13 (depends on 7)

The composition of claim 7, wherein the Ca2+ or a salt thereof and leucine are present in the oral pharmaceutical dosage form in a molar ratio of Ca2+:leucine:linaclotide of about 57-63:28-32:1.

### Claim 14 (depends on 9)

The composition of claim 9, wherein the Ca2+ or a salt thereof and leucine are present in the oral pharmaceutical dosage form in a molar ratio of Ca2+:leucine:linaclotide of about 57-63:28-32:1.

### Claim 15 (depends on 10)

The composition of claim 10, wherein the Ca2+ or a salt thereof and leucine are present in the oral pharmaceutical dosage form in a molar ratio of Ca2+:leucine:linaclotide of about 57-63:28-32:1.

### Claim 16 (depends on 11)

The composition of claim 11, wherein the Ca2+ or a salt thereof and leucine are present in the oral pharmaceutical dosage form in a molar ratio of Ca2+:leucine:linaclotide of about 57-63:28-32:1.

### Claim 17 (depends on 9)

The composition of claim 9, wherein the oral pharmaceutical dosage form further comprises an oxidation product having a structure of:
in an amount from about 0.05% to about 5% by weight relative to the total weight of the dosage form.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the oxidation product in present in the dosage form in an amount of about 0.05% to about 2% relative to the total weight of the dosage form.

### Claim 19 (depends on 17)

The composition of claim 17, wherein the oxidation product in present in the dosage form in an amount of about 0.05% to about 1% relative to the total weight of the dosage form.

### Claim 20 (depends on 7)

The composition of claim 7, wherein the Ca2+ or a salt thereof and leucine are present in the oral pharmaceutical dosage form in a molar ratio of Ca2+:leucine:linaclotide of about 57-63:28-32:1, wherein the formaldehyde scavenger compound is selected from the group consisting of d-meglumine and histidine, and wherein the peptide of formula (I) is present in the oral pharmaceutical dosage form in an amount of about 0.001 to about 1 wt. % relative to the total weight of the dosage form.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the peptide of formula (I) is present in the oral pharmaceutical dosage form in an amount of about 0.001 to about 0.75 wt. % relative to the total weight of the dosage form.

### Claim 22 (depends on 20)

The composition of claim 20, wherein the peptide of formula (I) is present in the oral pharmaceutical dosage form in an amount of about 0.001 to about 0.5 wt. % relative to the total weight of the dosage form.

### Claim 23 (depends on 23)

The composition of claim 23, wherein the formaldehyde scavenger compound is selected from the group consisting of leucine, glycine, aspartame, d-meglumine, histidine, asparagine, proline, or a mixture thereof.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the formaldehyde scavenger compound is d-meglumine, histidine or a mixture thereof.

### Claim 25 (depends on 23)

The composition of claim 23, wherein the formaldehyde scavenger compound is d-meglumine.

### Claim 26 (depends on 23)

The composition of claim 23, wherein the formaldehyde scavenger compound is histidine.

### Claim 27 (depends on 28)

The composition of claim 28, wherein the formaldehyde scavenger compound is present in the linaclotide composition in molar ratio of formaldehyde scavenger compound to linaclotide between 3:1 and 1:1.
